Equibles does not estimate personal net worth.
Get an email with a short summary when Kymera Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get KYMR alertsBruce Jacobs is recorded as CFO at Kymera Therapeutics, Inc. (KYMR). The newest filing on record that lists Bruce Jacobs as CFO at Kymera Therapeutics, Inc. (KYMR) is dated April 29, 2026. The proxy statement of Kymera Therapeutics, Inc. reports total compensation of $2,903,236 for Bruce Jacobs in fiscal 2025, including a base salary of $500,000. Disclosed compensation is on record for 6 fiscal years. Bruce Jacobs has spoken on 16 earnings calls and 3 other investor events across 1 company, most recently for Kymera Therapeutics, Inc. on September 14, 2026. Kymera Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Kymera Therapeutics, Inc. includes Jeremy Chadwick (COO), Jeremy Chadwick, Ph.D. (COO), Brian R. Adams (General Counsel) and 7 others.
“Probably going to take just about the next 10 to 15 minutes to give you a quick overview of Chimera, where we've been, and probably more importantly, where we're going.”
“As I walk through the second quarter results, please refer to the tables included in the press release, which was issued earlier this morning.”
“Maybe I'll start, and Jared can chime in. So it's a good time for that question. And Chimera actually, last week, celebrated our 10-year anniversary.”
“So, Ellie, so first of all, thanks for having us. I think this is the OG Miami March conference, so we're happy to be ending our week here. So thank you. Yeah, so it's a good time to ask that question.”
“As I walk through the fourth quarter results, please reference the tables found in today's press release, which was filed this morning. Collaboration revenue in the fourth quarter of 2025 of $2.9 million is attributable to our Gilead partnership.”
Start not stated–present
Last confirmed April 29, 2026
Biotechnology · Healthcare
CFO
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Kymera Therapeutics, Inc. (KYMR) | CFA, MBA Chief Financial Officer | $500,000 | $2,903,236 |
| 2024 | Kymera Therapeutics, Inc. (KYMR) | CFA, MBA Chief Financial Officer | $481,000 | $7,140,817 |
| 2023 | Kymera Therapeutics, Inc. (KYMR) | CFA, MBA Chief Financial Officer | $470,000 | $4,155,156 |
| 2022 | Kymera Therapeutics, Inc. (KYMR) | CFA, MBA Chief Financial Officer | $441,738 | $2,893,316 |
| 2021 | Kymera Therapeutics, Inc. (KYMR) | CFA, MBA Chief Financial Officer | $415,539 | $4,599,562 |
| 2020 | Kymera Therapeutics, Inc. (KYMR) | CFA, MBA Chief Financial Officer | $369,020 | $1,262,902 |
